Clinical Trial to Evaluate and Compare the Therapeutic Efficacy of Coded Unani Drug UNIM–105 with Control Drug UNIM–106 in Iltehab-eKabid Haad (Acute Infective Hepatitis) Patients
Zaheer Ahmed, Abdul Kareem, Kabeeruddin, Shahida, Aslam, D. Gracias, G. Sultana, Javid and Jameeluddin
Hippocratic Journal of Unani Medicine
Hippocratic Journal of Unani Medicine July - September 2016, Vol. 11 No. 3, Pages 45-67
Infective hepatitis (Iltehab-e-Kabid Haad) has been known chiefly as a sporadic, endemic and epidemic disease occurring in civilian populations all over the world. Infective hepatitis is the inflammation of the liver due to infection by viral and other agents. It is estimated that approximately 1.4 million persons die each year from various forms of viral hepatitis. No specific treatment is available for Infective viral hepatitis in conventional medicine. Supportive treatment including hospitalization is indicated for people with severe clinical manifestations. However, the drugs which are available are expensive and produce undue side effects. Many herbal preparations are claimed to be useful in the treatment of Iltehab-e- kabid Haad (infective hepatitis), however, no scientific data are available in support of these claims. The present study was undertaken to evaluate the therapeutic efficacy of coded Unani drug “UNIM-105” and to compare it with that of a standard drug “Ictrus (UNIM-106)” in patients of infective hepatitis. 165 cases in Group-I received the drug UNIM-105 and 133 cases in Group-II received the drug UNIM -106 in a dose of 1gm (2 capsules of 500mg in each group) orally thrice daily for a varying period of 30 and 40 days. The criteria of selection of cases for the study, the drug dosage, duration of treatment and follow-ups were uniform for both the groups. Age, gender and chronicity of disease wise distribution of patients were almost similar in both the groups. Subsidence of clinical sign & symptoms of Infective hepatitis was observed in patients after 10 days of treatment either with UNIM-105 or UNIM-106. Increased levels of serum bilirubin, SGOT &SGPT observed at base-line registered significant decline (< 0.001) towards normalcy during the course of treatment with UNIM-105 as well as with UNIM-106. Comparison of the results observed with drugs UNIM-105&UNIM-106 in the clinical study has revealed that the therapeutic efficacy exhibited by the drugs in terms of improvement in clinical as well as laboratory parameters were almost equal with no adverse effects.